Header Forschung

Neurosurgery

The Department of Neurosurgery at the Carl Gustav Carus Faculty of Medicine at TU Dresden is one of the leading neurosurgical centers in Europe and embedded in the certified Neuro-Oncology Center of the Dresden Medical Campus. Our goal is to provide the best medical care, to advance our understanding of brain tumors as well as to develop novel treatment strategies. We offer highest medical expertise in handling malignancies of the brain and other diseases of the peripheral and central nervous system. Every year about 2000 patients are treated in 3 most modern operation theaters. We constantly offer our patients the newest treatment modalities including participation in innovative clinical studies.

The main research activities of our Department include genetic analysis and molecular diagnostics of brain tumors and of novel gene therapy and immunotherapy treatment approaches to detect and destroy tumor cells. Furthermore, as part of the interdisciplinary Molecular Neuroimaging Laboratory of the Medical Campus, we focus on the development of next generation optical imaging methods to improve detection of tumor cells and of normal brain function during surgery. The research activities of our Clinic and Research Laboratories are funded by the German Cancer Foundation (DKH), DFG, BMBF/VDI and others and are implemented in the German Consortium for Translational Cancer Research (DKTK) and the National Center for Tumor diseases (NCT).

Magnetic resonance image of brain tumor

Figure 1: From left to right: Magnetic resonance image of a brain tumor // novel marker-free detection of brain tumor cells // Visualization of brain function during open brain surgery

Schematic presentation of immunotherapy for glioblastoma using CAR-NK cells.

Figure 2: Schematic presentation of immunotherapy for glioblastoma using CAR-NK cells. Single chain fragment variables (scFv) specific for a tumor antigen are fused to a NK signaling adapter resulting in a chimeric antigen receptor (CAR). The genetic transfer of the CAR into NK cells is accomplished using viral vectors. Upon expression of the CAR, NK cells can recognize tumor antigen on the cell surface and subsequently destroy tumor cells using cytotoxic molecules or death ligands.

Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma.
Stasik S, Juratli TA, Petzold A, Richter S, Zolal A, Schackert G, Dahl A, Krex D, Thiede C.Stasik S, et al. Neoplasia. 2020 Dec;22(12):800-808. doi: 10.1016/j.neo.2020.10.010. Epub 2020 Nov 2.Neoplasia. 2020. PMID: 33142244 Free PMC article.

Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R, Vordermark D, Hassel JC, Krex D, Wendl C, Schadendorf D, Sickmann T, Rieken S, Pukrop T, Höller C, Eigentler TK, Meier F.Gutzmer R, et al. Cancer Treat Rev. 2020 Sep;89:102083. doi: 10.1016/j.ctrv.2020.102083. Epub 2020 Jul 18.Cancer Treat Rev. 2020. PMID: 32736188 Review.

Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis.
Schau I, Michen S, Hagstotz A, Janke A, Schackert G, Appelhans D, Temme A.Schau I, et al. Among authors: temme a. Sci Rep. 2019 Mar 1;9(1):3299. doi: 10.1038/s41598-019-40032-8.Sci Rep. 2019. PMID: 30824859 Free PMC article.

Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status.
Uckermann O, Juratli TA, Galli R, Conde M, Wiedemuth R, Krex D, Geiger K, Temme A, Schackert G, Koch E, Steiner G, Kirsch M.Uckermann O, et al. Among authors: temme a. Clin Cancer Res. 2018 Jun 1;24(11):2530-2538. doi: 10.1158/1078-0432.CCR-17-1795. Epub 2017 Dec 19.Clin Cancer Res. 2018. PMID: 29259030

TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study.
Juratli TA, Stasik S, Zolal A, Schuster C, Richter S, Daubner D, Juratli MA, Thowe R, Hennig S, Makina M, Meinhardt M, Lautenschlaeger T, Schackert G, Krex D, Thiede C.Juratli TA, et al. Clin Cancer Res. 2018 Nov 1;24(21):5282-5291. doi: 10.1158/1078-0432.CCR-17-3717. Epub 2018 Jun 25.Clin Cancer Res. 2018. PMID: 29941484